8-K: Precision BioSciences Extends Cash Runway, Advances Pipeline

Precision BioSciences reports $137 million cash, extending its runway through 2028, and outlines key clinical milestones for its gene editing programs in 2026.

Summary

• Unaudited cash, cash equivalents, and restricted cash totaled approximately $137 million as of December 31, 2025.
• Existing cash and equivalents, potential near-term consideration from licensees, continued fiscal and operating discipline, and availability of the at-the-market (ATM) facility are expected to extend the cash runway through 2028.
• The Phase 1/2a ELIMINATE-B trial for PBGENE-HBV (chronic Hepatitis B) is ongoing across multiple dosing cohorts, with additional biopsy data expected in the first half of 2026.
• The company expects to complete dosing Cohorts 3, 4, and 5 and choose the optimal dosing regimen for PBGENE-HBV to achieve the goal of stopping nucleos(t)ide analog treatment and begin Part 2 expansion of the trial.
• The Phase 1/2 FUNCTION-DMD clinical trial for PBGENE-DMD (Duchenne Muscular Dystrophy) is expected to dose its first patient in late-Q1 or early-Q2 2026, pending IND clearance in Q1 2026.
• Initial data from multiple PBGENE-DMD patients is expected by year-end 2026.
• Partnered program ECUR-506 (iECURE) for neonatal onset OTC deficiency received FDA Regenerative Medicine Advanced Therapy (RMAT) designation and alignment on Biologics License Application (BLA) endpoints; data expected in the first half of 2026.
• Precision received an $8 million milestone payment in Q4 2025 from Imugene for Azer-Cel's progress towards a pivotal study for diffuse large B-cell lymphoma.
• Precision is eligible for a $7.5 million near-term clinical milestone payment from TG Therapeutics for Azer-Cel's Phase 1 trial in progressive multiple sclerosis.

Sentiment

Score: 8

Explanation: The filing presents a strong financial position with an extended cash runway, significant clinical progress across multiple programs, and positive updates from partnered assets, including milestone payments. The outlook for 2026 includes several key data readouts and trial advancements, indicating robust operational execution and potential for future value creation.

Positives

• Strong unaudited cash, cash equivalents, and restricted cash of approximately $137 million as of December 31, 2025.
• Projected cash runway extended through 2028, providing financial stability to fund key data milestones.
• PBGENE-HBV trial shows clear positive evidence of dose-dependent effects and antiviral activity, including the first molecular evidence of successful viral DNA gene editing in patients.
• PBGENE-HBV safety data indicates no dose-limiting toxicities at doses up to 0.8 mg/kg, with predictable, manageable, and transient adverse events.
• PBGENE-DMD, a novel first-in-class gene editing therapy, is on track to enter the clinic in early 2026.
• iECURE's ECUR-506, utilizing Precision's ARCUS nuclease, received FDA RMAT designation and BLA endpoint alignment, indicating significant regulatory progress.
• Precision received an $8 million milestone payment from Imugene in Q4 2025, validating its partnered programs.
• Precision is eligible for an additional $7.5 million near-term clinical milestone from TG Therapeutics.

Risks

• The reported cash balance is an unaudited and preliminary estimate, subject to change upon finalization of full financial results.
• Forward-looking statements involve known and unknown risks, uncertainties, and other important factors, including those detailed in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and Quarterly Reports on Form 10-Q.
• The progression and success of the company's programs and product candidates are not guaranteed.
• There is a limited ability or inability to assess the safety and efficacy of product candidates.
• The company's dependence on its ARCUS technology carries inherent risks.
• The initiation, cost, timing, progress, achievement of milestones, and results of research and development activities and preclinical and clinical studies, including clinical trial and investigational new drug applications, are uncertain.
• The ability to advance product candidates into, and successfully design, implement, and complete, clinical trials is a significant risk.
• Interim top-line and initial data that are announced or published may change.
• Reliance on third parties, including suppliers and manufacturers, poses operational risks.

Future Outlook

The company expects its existing cash, potential near-term consideration from licensees, continued fiscal and operating discipline, and availability of its at-the-market facility to extend its cash runway through 2028. Significant clinical milestones are anticipated in 2026, including additional biopsy data for PBGENE-HBV in the first half, completion of dosing cohorts and selection of an optimal regimen for Part 2 expansion of ELIMINATE-B, IND clearance for PBGENE-DMD in Q1, first patient dosing for FUNCTION-DMD in late-Q1/early-Q2, and initial data from multiple PBGENE-DMD patients by year-end.

Management Comments

• "We continue to make steady, disciplined progress across our clinical-stage programs. With multiple dosing cohorts underway in our global Phase 1/2a ELIMINATE-B trial, our first-in-class gene editing approach for DMD entering the clinic in early 2026, and cash runway through 2028, we expect continued operational excellence this year with clear clinical and regulatory milestones for these potentially transformative therapies." Michael Amoroso, Chief Executive Officer.
• "We continue to advance PBGENE-HBV through Part 1 of the ELIMINATE-B dose-finding study and are encouraged by the activity we are seeing at all dose levels. As part of our dose optimization efforts, we are evaluating different levers for PBGENE-HBV across escalating doses, frequency of doses, and number of administrations in order to maximize the therapeutic index of PBGENE-HBV and start the expansion phase. We look forward to sharing further details at hepatitis-focused medical conferences in 2026." Cindy Atwell, Chief Development and Business Officer.

Industry Context

Precision BioSciences operates in the highly competitive and rapidly evolving gene editing and gene therapy space. Its proprietary ARCUS platform is positioned as a differentiated technology, aiming to deliver lasting cures for high unmet medical needs. The progress in chronic Hepatitis B and Duchenne Muscular Dystrophy aligns with a broader industry trend towards developing curative therapies for genetic and infectious diseases. The company's strategy of leveraging its platform through collaborations with iECURE, Imugene, and TG Therapeutics is a common approach in biotech to de-risk and accelerate development, while also generating non-dilutive funding through milestone payments.

Comparison to Industry Standards

• PBGENE-HBV is uniquely designed to potentially achieve a complete cure of hepatitis B by eliminating cccDNA and inactivating integrated HBV DNA, differentiating it from existing antiviral treatments.
• PBGENE-DMD is a novel first-in-class gene editing therapy utilizing a gene excision approach, which is clearly differentiated from existing microdystrophin and exon skipping treatments for Duchenne Muscular Dystrophy, such as those developed by Sarepta Therapeutics and Pfizer.
• iECURE's ECUR-506 for neonatal onset OTC deficiency received FDA Regenerative Medicine Advanced Therapy (RMAT) designation, a status granted to therapies that address serious conditions and have the potential to address unmet medical needs, similar to other expedited pathways for breakthrough therapies in rare diseases.
• Azer-Cel's progress towards a pivotal study for diffuse large B-cell lymphoma (DLBCL) positions it in the competitive CAR T-cell therapy market, but as an allogeneic (off-the-shelf) option, it offers potential advantages in accessibility and manufacturing over autologous CAR T-cell therapies like Yescarta (Gilead/Kite) and Kymriah (Novartis).

Stakeholder Impact

• Shareholders: Potential positive impact due to extended cash runway, clinical progress, and potential for future value inflection points from pipeline advancements and milestone payments.
• Patients (HBV, DMD, OTC deficiency, DLBCL, MS): Potential for new, transformative gene editing therapies if clinical trials are successful, addressing high unmet medical needs.
• Employees: Continued stability and progress in research and development, supporting ongoing employment and scientific innovation.
• Licensees/Partners (iECURE, Imugene, TG Therapeutics): Continued collaboration and progress on partnered programs, potentially leading to further milestone payments and successful product development.

Next Steps

• Additional biopsy data for PBGENE-HBV expected in the first half of 2026.
• Complete dosing Cohorts 3, 4, and 5 for PBGENE-HBV.
• Choose optimal dosing regimen for PBGENE-HBV to achieve the goal of stopping nucleos(t)ide analog treatment and begin Part 2 expansion of the ELIMINATE-B trial.
• IND clearance for PBGENE-DMD in Q1 2026.
• Dose the first patient in the FUNCTION-DMD Phase 1/2 clinical trial in late-Q1 or early-Q2 2026.
• Initial data from multiple FUNCTION-DMD patients expected by year-end 2026.
• Meet with the FDA to align on a regulatory path forward for PBGENE-DMD following supportive data from at least 10 patients.
• iECURE expects to release data from the OTC-HOPE study in the first half of 2026.
• Further details on PBGENE-HBV to be shared at hepatitis-focused medical conferences in 2026.

Key Dates

Recommendation

The company demonstrates a strong financial position with an extended cash runway through 2028, which is critical for a clinical-stage biotechnology firm. Significant clinical progress in its lead programs, PBGENE-HBV and PBGENE-DMD, along with positive updates and milestone payments from partnered assets, provide a solid foundation. However, as a clinical-stage company, the stock remains subject to inherent risks associated with clinical trial outcomes, regulatory approvals, and the competitive landscape. While the outlook is positive, further de-risking through successful clinical data readouts is needed for a more definitive investment stance, hence a 'hold' recommendation at this juncture.

Keywords

Gene editing, ARCUS platform, Chronic Hepatitis B, Duchenne Muscular Dystrophy, PBGENE-HBV, PBGENE-DMD, Clinical trials, Biotechnology, Cash runway, SEC filing, DTIL, Rare diseases, Orphan drugs, CAR T-cell therapy